Semaglutide can melt fat. It can also take muscle with it. A large new phase 2 trial in The Lancet asked whether blocking the body's "brakes" on muscle growth could prevent that loss. The answer is a qualified yes, and one version of the treatment came with a safety signal that deserves attention.
Here is what the COURAGE trial found, what it didn't, and what GLP-1 users can actually do today.
The Problem: Rapid Weight Loss Isn't Only Fat
The weight loss from GLP-1 receptor agonists comes with pronounced muscle loss. In COURAGE, people on semaglutide plus placebo lost 6.6% of their lean mass at 26 weeks (95% CI −7.4 to −5.7). In the 52-week part of the trial, the placebo group's lean mass fell 7.3%.
Lean mass is not identical to skeletal muscle, but it is the trial's primary measure and a standard proxy.
The Idea: Block Myostatin (GDF8) and Activin A
GDF8, better known as myostatin, and activin A act through ActRIIA/B receptors as negative regulators of muscle mass. Regeneron tested two antibodies:
- Trevogrumab, which blocks GDF8 and was given weekly by subcutaneous injection.
- Garetosmab, which blocks activin A and was given intravenously every 4 weeks.
The Trial: 975 People, Two Parts
The study was a double-blind, placebo-controlled phase 2 trial at 60 US sites. It enrolled 975 adults with obesity (BMI ≥30), with a mean age of 49 and a mean BMI of 36.7. Sixty-four percent were female. Everyone took semaglutide, titrated to 2.4 mg weekly.
- Part A (26 weeks, n=605): placebo, trevogrumab 200 mg, trevogrumab 400 mg, or trevogrumab 400 mg plus garetosmab 10 mg/kg.
- Part B (52 weeks, n=376): placebo, trevogrumab 25 mg, or trevogrumab 75 mg.
The Headline Numbers: Lean Mass
The figures below are estimated treatment differences versus semaglutide plus placebo.
Part A (26 weeks):
- Trevogrumab 200 mg: +3.1% (95% CI 1.9 to 4.3)
- Trevogrumab 400 mg: +2.7% (1.5 to 4.0)
- Trevogrumab 400 mg plus garetosmab: +4.5% (3.1 to 5.9)
Part B (52 weeks):
- Trevogrumab 25 mg: +1.5% (−0.3 to 3.3), not statistically significant
- Trevogrumab 75 mg: +3.1% (1.3 to 4.9)
The treatments reduced lean-mass loss but did not eliminate it. The abstract does not report absolute lean-mass change for the treatment arms, so any "net loss" figure for them would be our own arithmetic.
Fat Loss and Weight: A Surprise
Muscle-sparing drugs are sometimes assumed to trade away fat loss. Here the opposite happened in some arms.
- The placebo group lost 15.6% of fat mass in part A.
- Trevogrumab 400 mg alone produced significantly greater fat loss (ETD −3.4%).
- The trevogrumab plus garetosmab combination produced a much larger additional fat loss (ETD −11.7%).
- Bodyweight fell 10.6% on semaglutide plus placebo. Only the combination significantly improved on that, by an extra 2.7 percentage points.
- No other part A group and no part B group differed significantly in fat mass or bodyweight.
The Catch: The Combination's Safety Profile
Trevogrumab alone, at 25, 75, 200 or 400 mg, was generally well tolerated, with a safety profile similar to semaglutide plus placebo. Gastrointestinal events were the most common and occurred at similar rates across groups. Most adverse events were mild to moderate.
The trevogrumab 400 mg plus garetosmab group was different:
- Serious adverse events: 14 of 149 (9%)
- Treatment discontinuations: 48 of 149 (32%)
- Muscle spasms: 61 of 149 (41%), versus 8% (23 of 299) in the trevogrumab-alone groups and 5% (7 of 151) on placebo
- Deaths: two during the study, both in this group. The investigators did not identify a causal association.
The authors conclude that the combination "did not have favourable safety and tolerability." They frame trevogrumab alone as the proof of concept.
Caveats
- Sponsorship: The trial was funded by Regeneron, and many authors are Regeneron employees and shareholders.
- Phase 2: The primary endpoints were body composition and weight, not function. The authors say further study is needed to see whether preserved lean mass translates into better physical function and metabolic health.
- Not approved: Neither antibody is approved for this use. You cannot get them as a supplement or prescription.
- Withdrawal phase: Part A included a 26-week period after semaglutide was stopped, but the abstract reports no results from it.
What This Means for GLP-1 Users Now
The following is general guidance, not a finding from this study, which tested neither exercise nor diet.
- Do not chase this drug class. There is no dose, timing or "who it's for" because nothing is available outside trials.
- Prioritize protein and resistance training. These are the widely recommended, accessible ways to defend muscle during weight loss. Discuss the protein target and exercise plan with your clinician or a dietitian, especially if you have kidney disease.
- Track more than the scale. Strength, function and, where possible, body composition tell you more than weight alone.
Timeline
The abstract gives no approval timeline. COURAGE is active but not recruiting. Because the combination's safety profile was concerning and function was not assessed, further trials would be needed before any regulator could consider these drugs. Treat this as a promising early signal, not an imminent option.